![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Highly Active Antiretroviral Therapy (HAART) is composed of several drugs in the antiretroviral class to better treat human immunodeficiency virus type 1 (HIV-1) patients. The estimation of CD4+ T cell counts and HIV-1 viral load in plasma is required to evaluate the treatment success of a specific HAART.
Methodology: The study included the effects of NRTIs (nucleoside reverse transcriptase inhibitors) and novel protease inhibitors (HAART) on normal control subjects and HIV-1 positive subjects from SGPGIMS, Lucknow, with different age groups and genders. Furthermore, the study was conducted by the estimation of HIV through ELISA, measurement of absolute CD4+ cell count, and the measurement of viral load through qRT-PCR. Furthermore, NRTIs (Retrovir and Epivir) were administered orally one tablet daily in the morning followed by newly FDA-approved protease inhibitors (fosamprenavir and darunavir) orally in the evening at the same dose. Furthermore, CD4+T cell counts and HIV-1 viral load were investigated and correlated in patients with different genders and age groups.
Results: Administration of NRTIs and novel protease inhibitors (HAART) in HIV patients had a significant effect on the CD4+ cell count in various age intervals among males and females.
The mean comparison of viral load distribution based on gender in CD4 +ve patients in the case group exhibited a viral load higher in females compared to males, indicating a statistically significant difference between males and females (p<0.05). A notable association between virological and immunological parameters was observed with a reciprocal relationship between viral load and CD4 cell count in CD4 +ve patients, demonstrating multiple correlation coefficients with an R-value of 0.853.
Conclusion: The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity.
[http://dx.doi.org/10.3889/oamjms.2019.479] [PMID: 31316662]
[http://dx.doi.org/10.1016/0167-5699(96)10049-9] [PMID: 8854558]
[http://dx.doi.org/10.3851/IMP3155] [PMID: 28291735]
[http://dx.doi.org/10.4049/jimmunol.1002000] [PMID: 21257970]
[http://dx.doi.org/10.1016/S2352-3018(15)00006-5] [PMID: 26424550]
[http://dx.doi.org/10.1097/MD.0000000000003108] [PMID: 26986155]
[http://dx.doi.org/10.1371/journal.pone.0097011] [PMID: 24816636]
[http://dx.doi.org/10.1086/504718] [PMID: 16741879]
[PMID: 30766213]
[http://dx.doi.org/10.1056/NEJMoa1506816] [PMID: 26192873]
[http://dx.doi.org/10.1177/0956462419834129] [PMID: 30961467]
[http://dx.doi.org/10.1001/jama.2018.21167] [PMID: 30629090]
[http://dx.doi.org/10.1371/journal.pmed.1001095] [PMID: 21949643]
[http://dx.doi.org/10.3904/kjim.2015.30.5.705] [PMID: 26354065]
[http://dx.doi.org/10.1056/NEJMoa062360] [PMID: 17135583]
[http://dx.doi.org/10.1016/j.cca.2016.02.022] [PMID: 26940950]
[http://dx.doi.org/10.3390/pathogens9121047] [PMID: 33322208]
[http://dx.doi.org/10.1056/NEJMoa0903175] [PMID: 19828532]
[http://dx.doi.org/10.1056/NEJM199610313351803] [PMID: 8857018]
[http://dx.doi.org/10.2165/00007256-199928060-00002] [PMID: 10623982]
[http://dx.doi.org/10.1177/00333549071220S106] [PMID: 17354525]
[http://dx.doi.org/10.1371/journal.pone.0097596] [PMID: 24840662]
[http://dx.doi.org/10.1089/apc.1999.13.717] [PMID: 10743535]
![Wayfinder Image](/images/wayfinder.jpg)